Malaysia
Search
Sign In
Change Password
Points
Sign Out
Diabetes is a complex disease that is best treated by a multidisciplinary team of healthcare professionals. But even with their help, patients with diabetes often struggle to comply with a bewildering array of medications at home. In conjunction with World Diabetes Day on 14 November, Lim Phei Ching speaks with MIMS about her experiences in 13 years as a pharmacist in Hospital Pulau Pinang’s Diabetes Medication Therapy Adherence Clinic (DMTAC).
In conjunction with World Diabetes Day on 14 November, diabetes solutions provider Ascensia Diabetes Care and local retail pharmacy chain Alpro Pharmacy have launched a first-in-kind diabetes management programme in Malaysia.
Patients with type 2 diabetes (T2D) and severe obesity may have a greater chance of complete T2D remission 1 year after gastric bypass rather than sleeve gastrectomy, according to results of the Oseberg* trial.
Upfront combination therapy with metformin and the DPP-4* inhibitor vildagliptin may improve glycaemic durability in patients newly diagnosed with type 2 diabetes (T2D) compared with sequential therapy with metformin monotherapy followed by vildagliptin, results from the VERIFY** trial showed.
In patients with type 2 diabetes (T2D) inadequately controlled on metformin, semaglutide may have a greater impact than canagliflozin in reducing HbA1c levels and bodyweight, according to the phase IIIb SUSTAIN 8* trial presented at EASD 2019.
The incidence of cardiovascular (CV) death, nonfatal myocardial infarction (MI), or nonfatal stroke (three-point MACE*) was comparable in individuals with early stage type 2 diabetes (T2D) who received the DPP-4** inhibitor linagliptin or the sulfonylurea glimepiride in addition to usual care, according to results of the CAROLINA*** trial.
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.
